BRPI0510317A - anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso - Google Patents

anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso

Info

Publication number
BRPI0510317A
BRPI0510317A BRPI0510317-7A BRPI0510317A BRPI0510317A BR PI0510317 A BRPI0510317 A BR PI0510317A BR PI0510317 A BRPI0510317 A BR PI0510317A BR PI0510317 A BRPI0510317 A BR PI0510317A
Authority
BR
Brazil
Prior art keywords
antigen
methods
c4bp
binding
mediated
Prior art date
Application number
BRPI0510317-7A
Other languages
English (en)
Inventor
Mohammad Luqman
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of BRPI0510317A publication Critical patent/BRPI0510317A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)

Abstract

ANTICORPOS MONOCLONAIS ANTI-CD40 ANTAGONISTAS E MéTODOS PARA SEU USO. São fornecidas composições e métodos para inibir atividades direcionadas a CD40 que são mediadas via ligação de C4BP a CD40. As composições da invenção incluem anticorpos anti-CD40, ou fragmentos de ligação a antígeno desses, que têm as seguintes características: 1) são livre de atividade agonista de CD40 significativa quando ligados ao antígeno de CD40; e 2) são capazes de se ligar específicamente ao antígeno de CD40 expresso na superfície de células, onde essa ligação ao antígeno de CD40 bloqueia a sinalização de CD40 mediada por C4BP, dessa forma inibindo uma ou mais atividades direcionadas a CD40. Esses anticorpos anti-CD4O antagonistas podem ser usados de forma eficaz para tratar doenças associadas a CD40 que são mediadas por estímulo de C4BP da sinalização de CD40, incluindo cânceres, como cânceres relacionados à célula B e tumores sólidos, e doenças ou distúrbios que têm um componente autoimune e/ou inflamatório, incluindo rejeição de transplantes de órgãos e tecidos.
BRPI0510317-7A 2004-04-27 2005-04-27 anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso BRPI0510317A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56577504P 2004-04-27 2004-04-27
PCT/US2005/014359 WO2006073443A2 (en) 2004-04-27 2005-04-27 Antagonist anti-cd40 monoclonal antibodies and methods for their use

Publications (1)

Publication Number Publication Date
BRPI0510317A true BRPI0510317A (pt) 2007-10-16

Family

ID=36579251

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510317-7A BRPI0510317A (pt) 2004-04-27 2005-04-27 anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso

Country Status (10)

Country Link
EP (1) EP1761311A2 (pt)
JP (1) JP2008509080A (pt)
KR (1) KR20070026522A (pt)
CN (1) CN101014386A (pt)
AU (1) AU2005323515A1 (pt)
BR (1) BRPI0510317A (pt)
CA (1) CA2564296A1 (pt)
MX (1) MXPA06012430A (pt)
RU (1) RU2006141632A (pt)
WO (1) WO2006073443A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008207898B2 (en) * 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
WO2009062054A1 (en) * 2007-11-09 2009-05-14 Novartis Ag Uses of anti-cd40 antibodies
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
RS57114B1 (sr) 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
MY165090A (en) 2011-04-21 2018-02-28 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20150106872A (ko) * 2012-11-05 2015-09-22 가부시키가이샤 레그이뮨 면역 관용 유도제
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
CN106573981A (zh) 2014-08-12 2017-04-19 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
EP3344655B1 (en) * 2015-09-01 2023-07-26 Boehringer Ingelheim International GmbH Use of anti-cd40 antibodies for treatment of lupus nephritis
WO2017059196A2 (en) 2015-09-30 2017-04-06 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use
EA039944B1 (ru) * 2016-01-27 2022-03-30 Бёрингер Ингельхайм Интернациональ Гмбх Применение антител к cd40 для лечения волчаночного нефрита
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
US11525005B2 (en) 2017-06-01 2022-12-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
WO2019198019A1 (en) * 2018-04-13 2019-10-17 Novartis Ag Anti-cd40 antibodies for use in prevention of graft rejection
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
US20220025060A1 (en) 2018-11-30 2022-01-27 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereof
KR20210097750A (ko) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
KR102356829B1 (ko) * 2019-01-30 2022-01-28 주식회사 에프엔씨티바이오텍 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273452T3 (es) * 1992-07-09 2007-05-01 Novartis Vaccines And Diagnostics, Inc. Anticuerpos monoclonales antagonistas contra la molecula humana cd40.
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same

Also Published As

Publication number Publication date
RU2006141632A (ru) 2008-06-10
WO2006073443A3 (en) 2006-10-12
WO2006073443A2 (en) 2006-07-13
AU2005323515A1 (en) 2006-07-13
EP1761311A2 (en) 2007-03-14
CA2564296A1 (en) 2006-07-13
CN101014386A (zh) 2007-08-08
JP2008509080A (ja) 2008-03-27
KR20070026522A (ko) 2007-03-08
MXPA06012430A (es) 2007-04-19

Similar Documents

Publication Publication Date Title
BRPI0510317A (pt) anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
BR112012033075A2 (pt) composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto.
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
NO20073182L (no) Indazol-karboksamidforbindelser
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
EA201170028A1 (ru) СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α
MY151191A (en) Novel antibodies
MA32975B1 (fr) Antagonistes de c5ar
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
DK1966244T3 (da) Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
DK2152690T3 (da) Pyridylpiperidinorexin-receptorantagonister
EA201692543A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
EA201100191A1 (ru) Композиции и способы применения терапевтических антител
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
CR11107A (es) INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1
WO2008010101A8 (en) Antagonist antibody against epha2 for the treatment of cancer
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
WO2011004028A3 (en) Tlr3 binding agents
EA200970818A1 (ru) Гетероциклические соединения, содержащие их композиции и способы их применения

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 39/395 (2006.01), A61P 35/02 (2006.01), C07K